Maria Koliver, MD
Internal Medicine · Newark, NJNPI 1043276827
Payments from drug & device makers
Across 377 payments — averaging $33.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$7K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- GSK$923
- AbbVie$597
- AstraZeneca$492
- plus $1K from 21 others
What the payments were for
- Food & beverage$5,78146%
- Education$6,73454%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 1 | $6,688 |
| Novo Nordisk | 88 | $1,272 |
| Lilly USA, LLC | 76 | $1,051 |
| GSK | 49 | $923 |
| AbbVie(2 entities) | 42 | $597 |
| AstraZeneca | 33 | $492 |
| Boehringer Ingelheim | 25 | $375 |
| Amgen | 12 | $178 |
| Abbott | 5 | $130 |
| Pfizer | 8 | $125 |
| Merck | 8 | $112 |
| Amarin Pharma, Inc. | 5 | $78 |
| Medtronic | 1 | $74 |
| Irhythm Technologies, Inc. | 3 | $71 |
| Novartis | 4 | $59 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Exact Sciences | 2 | $43 |
| Cvrx, Inc. | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Bayer | 1 | $20 |
| Cook Medical LLC | 1 | $20 |
| Althera Pharmaceuticals LLC | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$6,688
- Ozempic$118
How this compares
$12,515 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 212 | $230,327 |
| MounjaroTirzepatide | 137 | $154,882 |
| EliquisApixaban | 131 | $121,367 |
| JardianceEmpagliflozin | 105 | $117,527 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $79,601 |
| TrulicityDulaglutide | 52 | $72,778 |
| JanuviaSitagliptin Phosphate | 32 | $42,096 |
| XareltoRivaroxaban | 19 | $23,331 |
| JanumetSitagliptin Phos/Metformin Hcl | 23 | $20,340 |
| LinzessLinaclotide | 12 | $19,006 |
| VraylarCariprazine Hcl | 12 | $17,772 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $17,288 |
| FarxigaDapagliflozin Propanediol | 11 | $14,841 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $13,517 |
| Rosuvastatin Calcium | 479 | $12,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,272 | $230,327212 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,051 | $227,660189 claims |
| PfizerEliquis | $125 | $121,367131 claims |
| Boehringer IngelheimJardiance | $375 | $117,527105 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $923 | $93,118136 claims |
| MerckJanuvia, Janumet | $112 | $62,43655 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Brilinta | $492 | $41,91549 claims |
| AbbVieLinzess, Vraylar | $597 | $36,77824 claims |
| NovartisEntresto | $59 | $11,22811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Newark
- Helio PedroNewark$1.8M
- Amesika NyakuNewark$127K
- Christian EngellNewark$53K
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.